Wave Life Sciences (WVE) Consolidated Net Income (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Consolidated Net Income came in at -$69.4 million in Q2 2026, down 37.42% YoY from -$110.8 million in Q2 2025, and down 165.86% on a QoQ basis from -$26.1 million in Q1 2026.
Analysis
Wave Life Sciences (WVE) Consolidated Net Income (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Consolidated Net Income data on file, last reported at -$69.4 million in Q2 2026.
- Quarterly Consolidated Net Income fell 37.42% year-over-year to -$69.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$202.5 million (down 55.9% YoY) and the FY2025 annual result came in at -$204.4 million, down 110.68% from the prior year.
- Consolidated Net Income eased to -$69.4 million in Q2 2026, from -$26.1 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $29.3 million in Q4 2024 to a low of -$69.4 million in Q2 2026.
- A 5-year average of -$34.2 million and a median of -$38.4 million in 2022 frame the typical range for Consolidated Net Income.
- The widest YoY moves for Consolidated Net Income: up 279.7% in 2024, down 949.21% in 2024.
- Tracing WVE's Consolidated Net Income over 5 years: stood at -$43.7 million in 2022, then soared by 62.76% to -$16.3 million in 2023, then surged by 279.7% to $29.3 million in 2024, then slumped by 281.79% to -$53.2 million in 2025, then plunged by 30.42% to -$69.4 million in 2026.
- The last three Consolidated Net Income figures came in at -$69.4 million (Q2 2026), -$26.1 million (Q1 2026), and -$53.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Wave Life Sciences | 986.38 Mn | 618.37 Mn | - | -69.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -69.36 Mn |
| Mar 31, 2026 | -26.09 Mn |
| Dec 31, 2025 | -53.18 Mn |
| Sep 30, 2025 | -53.85 Mn |
| Jun 30, 2025 | -50.47 Mn |
| Mar 31, 2025 | -46.88 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | -61.78 Mn |
| Jun 30, 2024 | -32.92 Mn |
| Mar 31, 2024 | -31.56 Mn |
| Dec 31, 2023 | -16.28 Mn |
| Sep 30, 2023 | 7.28 Mn |
| Jun 30, 2023 | -21.10 Mn |
| Mar 31, 2023 | -27.41 Mn |
| Dec 31, 2022 | -43.71 Mn |
| Sep 30, 2022 | -39.00 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -37.81 Mn |
| Dec 31, 2021 | -34.79 Mn |
| Sep 30, 2021 | -6.23 Mn |